SCHEDULE: Armistice Capital Discloses Agios Pharmaceuticals Stake

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 4.57% of Agios Pharmaceuticals, Inc. common stock as of March 31, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the Reporting Persons, have filed a Schedule 13G, indicating their beneficial ownership of Agios Pharmaceuticals, Inc. common stock.
• The filing, dated March 31, 2026, shows that the Reporting Persons beneficially own 2,716,000 shares of common stock, representing 4.57% of the class.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own these shares.
• The Master Fund disclaims beneficial ownership due to the investment management agreement with Armistice Capital, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of ownership by an investment firm, without immediate positive or negative implications for the company's operations or financials.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant stake (4.57%) in Agios Pharmaceuticals, Inc., which could signal confidence or a strategic interest in the company.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control.

Negatives

• The Master Fund, the direct holder of the shares, explicitly disclaims beneficial ownership, which could imply a lack of direct control or strategic intent from the fund itself.

Risks

• While the filing states the shares were not acquired to influence control, any significant increase in stake by Armistice Capital could be perceived as an activist move, potentially leading to scrutiny or pressure on management.
• The nature of investment management agreements can sometimes lead to complex ownership structures and potential conflicts of interest, though not explicitly stated as a risk here.

Future Outlook

No specific forward-looking statements or guidance are provided in this Schedule 13G filing, which primarily concerns ownership disclosure.

Management Comments

• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Armistice Capital's interest in Agios Pharmaceuticals, a biotechnology company, which is a sector often subject to active investment strategies.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by Armistice Capital may influence market perception and potentially lead to increased trading volume or volatility.
• Management: The company's management may need to engage with Armistice Capital, especially if the firm's investment strategy evolves beyond passive holding.

Next Steps

• Further filings may be required if the Reporting Persons' ownership stake changes significantly.

Key Dates

Keywords

Schedule 13G, Agios Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, Investment Management, SEC Filing